Regeneron Stock (REGN) Higher Pre-Market As Earnings Await – What To Expect

Regeneron’s stock price (NASDAQ:REGN) is 2% higher in the pre-market ahead of earnings, after somewhat of a pause in momentum over the past few months.

Consensus sits at $10.56 EPS on $3.59B revenue, both below prior-year levels, creating a setup where execution clarity matters more than the magnitude of any beat.

The estimate trajectory into the print reflects caution. Refinitiv consensus moved from $10.60 to $10.56 over the final week of January, while Zacks reported a 4.61% downward revision over the prior 30 days. This reset follows three consecutive beats (Q2 and Q3 2025 each exceeded estimates by over 20%), suggesting the Street learned to price in operational volatility rather than extrapolate profitability surprises.

Management’s latest guidance, issued with Q2 results, targeted approximately 86% non-GAAP gross margin and $880M to $950M capex for FY 2025. A clean Q4 print requires holding those ranges while demonstrating progress on the EYLEA HD regulatory path and stabilizing the combined EYLEA franchise revenue trajectory.

[auto_nav]

Consensus Estimates

Consensus EPS of $10.56 sits 15.2% below the prior-year quarter, reflecting the combined weight of EYLEA franchise erosion and elevated operating expenses tied to pipeline advancement. The estimate range spans $7.61 to $10.57, a $2.96 spread that signals meaningful disagreement on how profitability from Dupixent collaboration economics and cost discipline will offset top-line pressure.

Management Guidance & Commentary

“The initial uptake of EYLEA HD has been strong as EYLEA patients transition to the higher dose.”

Management’s Q3 commentary framed the EYLEA franchise transition as progressing on plan, with EYLEA HD adoption offsetting legacy EYLEA declines driven by competition from Roche’s Vabysmo and affordability-driven share loss to compounded bevacizumab. The company disclosed preliminary Q4 U.S. EYLEA sales of $577M and EYLEA HD sales of $506M, implying combined franchise revenue of approximately $1.08B domestically.

“We plan to resubmit the marketing application for the pre-filled syringe version of EYLEA HD by January 2026.”

The pre-filled syringe resubmission timeline, announced after Q3 results, provides a dated plan of record for resolving the regulatory setback that pressured shares in Q2 2025. The FDA’s prior decline tied to process-related issues at a fill-finish site introduced manufacturing execution as a stock-moving variable, overriding fundamental earnings power.

Analyst Price Targets & Ratings

Wall Street remains largely bullish, with 82% of analysts rating shares a Buy or Strong Buy. The consensus target of $831.38 implies 11% upside from current levels, though targets range widely based on assumptions about EYLEA HD transition success and Dupixent growth sustainability.

Sector & Peer Comparison

Regeneron trades at 18.0x trailing earnings and 18.8x forward earnings, a premium to Amgen (15.2x / 14.8x) and Gilead (13.9x / 12.6x) but a discount to Vertex (22.1x / 20.3x). The company’s 32.1% profit margin sits between Amgen’s 28.4% and Vertex’s 41.2%, reflecting Regeneron’s collaboration model where Dupixent profits are shared with Sanofi rather than fully consolidated.

Regeneron’s corporate campus where key pipeline decisions are made

Earnings Track Record

Regeneron has beaten EPS estimates in 16 of the past 20 quarters, an 80% success rate with an average surprise of 8.9%. The trailing four quarters show three beats and one miss, with Q2 and Q3 2025 delivering outsized surprises of 52.7% and 22.3% respectively. These large beats followed Q1 2025’s 3.1% miss, which triggered an 8% single-day decline and reset expectations lower.

Post-Earnings Price Movement History

The average next-day move following earnings is 1.5%, with beats averaging 3.0% gains and misses averaging 1.4% declines. Q3 2025’s 7.0% gain on a 22.3% EPS beat stands out as the largest recent reaction, driven not just by the earnings surprise but by management’s announcement of a dated plan to resubmit the EYLEA HD pre-filled syringe application by January 2026.

Expected Move & Implied Volatility

The options market prices a 4.2% implied move for the earnings event, translating to a range of $715 to $778 based on the current stock price. This expected move sits slightly above the 12-month average post-earnings move of 3.8% but below the 7.0% realized move following Q3 2025’s beat. The setup suggests the market assigns roughly equal probability to upside and downside scenarios.

Expert Predictions & What to Watch

Key Outlook: Cautiously Constructive

The base case assumes consensus EPS of $10.56 is achievable given the company’s 80% historical beat rate and recent track record of exceeding lowered estimates. The critical variable is whether management can pair a beat with guidance that demonstrates the EYLEA-to-EYLEA HD transition is progressing on plan and the pre-filled syringe resubmission occurred on schedule.

Regeneron’s headquarters where critical EYLEA HD and pipeline decisions are made

Key Metrics to Watch

The combined EYLEA franchise revenue trajectory will determine whether the transition to EYLEA HD is progressing as management projects or facing accelerated erosion. Preliminary Q4 U.S. sales of $577M for legacy EYLEA and $506M for EYLEA HD imply combined domestic revenue of $1.08B, roughly flat sequentially. A decline below $1.05B would raise concerns that competitive pressure is overwhelming the HD transition.

For investors considering trading vs investing in Regeneron, the earnings announcement represents a critical inflection point. Those interested in learning to trade should note that biotech earnings often create significant volatility that can present both opportunities and risks for active traders.